Evidence map›Paper›PMID 38366800›Full record

ArticleCancer medicine2024

Association of blood cell-based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study.

Shiva Najjary, Johan M Kros, Bruno H Stricker, Rikje Ruiter, Yu Shuai, Robert Kraaij, Kristel Van Steen, Peter van der Spek, Casper H J Van Eijck, M Arfan Ikram and 1 more

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shiva NajjaryDepartment of Pathology and Clinical Bioinformatics, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, Rotterdam, the Netherlands.
Johan M KrosDepartment of Pathology and Clinical Bioinformatics, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-4727-0724
Bruno H StrickerDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Rikje RuiterDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Yu ShuaiDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Robert KraaijDepartment of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
Kristel Van SteenDepartment of Human Genetics, Laboratory for Systems Medicine, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Peter van der SpekDepartment of Pathology and Clinical Bioinformatics, The Tumor Immuno-Pathology Laboratory, Erasmus University Medical Center, Rotterdam, the Netherlands.
Casper H J Van EijckDepartment of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
M Arfan IkramDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Shahzad AhmadDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Funding

H2020 Marie Skłodowska-Curie Actions 860895
6 · The paper itself

Abstract

The immune response-gut microbiota interaction is implicated in various human diseases, including cancer. Identifying the link between the gut microbiota and systemic inflammatory markers and their association with cancer will be important for our understanding of cancer etiology. The current study was performed on 8090 participants from the population-based Rotterdam study. We found a significant association (false discovery rate [FDR] ≤0.05) between lymphocytes and three gut microbial taxa, namely the family Streptococcaceae, genus Streptococcus, and order Lactobacillales. In addition, we identified 95 gut microbial taxa that were associated with inflammatory markers (p < 0.05). Analyzing the cancer data, we observed a significant association between higher systemic immune-inflammation index (SII) levels at baseline (hazard ratio (HR): 1.65 [95% confidence interval (CI); 1.10-2.46, p ≤ 0.05]) and a higher count of lymphocytes (HR: 1.38 [95% CI: 1.15-1.65, p ≤ 0.05]) and granulocytes (HR: 1.69 [95% CI: 1.40-2.03, p ≤ 0.05]) with increased risk of lung cancer after adjusting for age, sex, body mass index (BMI), and study cohort. This association was lost for SII and lymphocytes after additional adjustment for smoking (SII = HR:1.46 [95% CI: 0.96-2.22, p = 0.07] and lymphocytes = HR: 1.19 [95% CI: 0.97-1.46, p = 0.08]). In the stratified analysis, higher count of lymphocyte and granulocytes at baseline were associated with an increased risk of lung cancer in smokers after adjusting for age, sex, BMI, and study cohort (HR: 1.33 [95% CI: 1.09-1.62, p ≤0.05] and HR: 1.57 [95% CI: 1.28-1.92, p ≤0.05], respectively). Our study revealed a positive association between gut microbiota, higher SII levels, and higher lymphocyte and granulocyte counts, with an increased risk of developing lung cancer.

Indexed as

Gastrointestinal MicrobiomeLung NeoplasmsBlood CellsBody Mass IndexHumansIncidenceInflammationcancer riskgut microbiotaimmune responseinflammatory markerssystemic inflammation index (SII)

Identifiers

PMID38366800
PMCPMC10904974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.